Bladder Cancer Stages and Survival Rates

Introduction to Bladder Cancer Staging

The American College of Radiology states that bladder cancer is divided into two major prognostic categories based on depth of invasion, with non-muscle invasive disease (Stages 0 and I) and muscle-invasive disease (Stages II-IV) having distinct outcomes 1, 2.

The American College of Radiology classifies bladder cancer into stages, including Stage 0/Ta (superficial papillary tumors), Stage 0is/Tis (carcinoma in situ), Stage I/T1 (tumors invading the lamina propria), Stage II (tumor invades the muscularis propria), Stage III (tumor extends through the muscle into perivesical fat or invades adjacent organs), and Stage IV (tumor invades pelvic/abdominal wall, has lymph node involvement, or distant metastases) 1, 2, 3, 4.

The overall 5-year survival rate for all bladder cancer stages combined is 78%, according to the American College of Radiology, with stage-specific survival rates as follows: Stage 0 (95% 5-year survival), Stage I (75% 5-year survival), Stage II (70% 5-year survival), Stage III (35% 5-year survival), and Stage IV (5% 5-year survival) 1, 2, 3.
For metastatic disease, the American College of Radiology reports a median survival of approximately 14 months with chemotherapy, with lymph node-only metastases having a 20.9% long-term disease-free survival and visceral metastases having a 6.8% long-term disease-free survival 5, 6.

The American College of Radiology identifies multiple tumor-related and patient-related factors that significantly impact survival, including tumor size (tumors ≥3 cm have decreased time to recurrence and progression), multifocality (multiple tumors increase recurrence rates), tumor grade (high-grade tumors have significantly worse recurrence-free intervals and progression rates), lymphovascular invasion (increases risk of lymph node metastases, recurrence, and decreased survival), and variant histology (squamous, micropapillary, nested, plasmacytoid, or neuroendocrine variants carry worse prognosis) 1, 2, 3.
For metastatic disease, the American College of Radiology notes that performance status is an independent prognostic factor for survival, the number of metastatic sites (≥2 organ sites predicts poor survival), and visceral vs. lymph node metastases (visceral metastases carry significantly worse prognosis) 6.

The National Comprehensive Cancer Network (NCCN) identifies that approximately 70-75% of newly diagnosed bladder cancers present as non-muscle invasive disease, which encompasses three distinct subtypes with varying prognoses 7
The critical challenge with NMIBC is the high recurrence rate, with 31-78% of patients experiencing recurrence within 5 years, and 10-20% progressing to muscle-invasive disease, as noted by the NCCN 7

Patients with Lynch syndrome (particularly MSH2 mutation carriers) have an estimated 5-20% lifetime risk of urothelial cancers, with highest risk in males, according to research published in Gut 8
The prognosis for urothelial tumors in Lynch syndrome patients depends on stage and grade, with 5-year survival exceeding 90% for non-invasive low-grade cancers and 60-70% for high-grade cancers, as reported in Gut 8

The American Academy of Family Physicians notes that the high recurrence rate of NMIBC necessitates rigorous surveillance protocols, as 50-70% of superficial tumors will recur after treatment 9
The American Academy of Family Physicians also recommends that tumor location and other factors be considered in surveillance protocols, as noted in their guidelines 10